# Phase 102 Status — Final Strategy Ranking

**Current state:** INITIALIZED — SOURCE ARTIFACTS REVIEWED; AUTOMATED VALIDATION PENDING  
**Promotion decision:** NO STRATEGY PROMOTED  
**Research scope:** existing committed artifacts only; no new data collection and no strategy retuning.

## Preliminary evidence-based priority

1. **TT-03 dynamic-N V5 — highest-priority candidate for further independent validation only.** Its Phase 50B source-faithful baseline has 200/201 candidate trades, 99.50% coverage, zero data errors, ₹89,669.15 net at the registered base scenario, ₹82,074.11 under +50% friction, and ₹60,834.11 under ₹20/order plus +50% friction. However, its published split has only **3 HOLD trades** (₹6,201.79), so it does not establish stable holdout expectancy and is not deployable evidence.
2. **Phase-32 stateful control — retained benchmark, not a fresh strategy promotion.** The frozen artifact reports 206 trades, net ₹63,672.58, profit factor 1.203, and max drawdown ₹61,960.87. Five tested model selectors had negative point-estimate paired deltas over 93 shared expiry blocks and bootstrap intervals crossing zero. A reconstruction mismatch is documented in Phase 38.
3. **TT-04 and TT-05 — no promotion due temporal instability.** Each showed positive net P&L in the short Phase 51-3 partial window through 2026-07-21, but the Phase 78 historical HOLD results were negative; 2026-07-28 and 2026-08-04 were missing from the complete requested window.
4. **TT-02 — not supported by the available partial window.** Negative under all four registered cost/friction scenarios.
5. **U02 ML options proxies — reject these specific tested implementations.** RF, XGBoost and LSTM5 each lost about 99.99% of their ₹100,000 account. Confidence intervals for mean trade P&L cross zero; this does not prove all possible versions of the papers fail.
6. **U05 seasonality proxy — strong negative signal, low sample.** Seven completed trades from 56 audited opportunities; net −₹283,669.90 on ₹300,000. Not enough trades to estimate a reliable long-run expectancy or disprove the original paper.
7. **Other modalities — not promoted or not strategy-P&L evidence.** Phase 83 had no registered defined-risk candidate pass; Phase 92's IV result failed independent replication and its combined synthetic-forward/OI block worsened prediction in its fixed sample; Phase 95/96 are forecast/underlying-index screens, not options-strategy validations.

This ordering prioritizes investigation, not live deployment. The ranking is conditional on the source reports and their stated limitations. No comparison combines incompatible P&L periods or calls open-interest/IV associations arbitrage.

## Required gates before closeout

- [ ] Add machine-readable evidence scorecard.
- [ ] Validate source artifacts and core arithmetic using Phase 102 standard-library tests.
- [ ] Commit consolidated report, script, workflow and audit outputs.
- [ ] Update README, root research log and error log.
- [ ] Review latest GitHub Actions run; update status regardless of success/failure.
- [ ] Close with either a bounded next validation plan or a no-go conclusion. No live strategy approval is permitted from synthesis alone.

## Links

- [Research plan](PHASE102_RESEARCH_PLAN.md)
- [Research log](PHASE102_RESEARCH_LOG.md)
- [Error log](PHASE102_ERROR_LOG.md)
- [Conversation log](PHASE102_CHAT_LOG.md)
- [Ranking report](results/phase102/PHASE102_REPORT.md)
- [Machine-readable scorecard](results/phase102/strategy_evidence_scorecard.csv)
- [Workflow](.github/workflows/phase102-final-strategy-ranking.yml)
